Sunday, October 17

Merck pill halves the effects of COVID-19 | Digital Trends Spanish

The pharmaceutical company Merck reported on Friday that its experimental pill against COVID-19 cut hospitalizations and deaths in half in recently infected people.

Due to these good results, the company said that it hopes very soon to ask the health authorities of the United States and other countries for authorization for its use.

Thus, this would be the first pill available to treat COVID-19.

“This is going to change the dialogue around how to manage COVID-19,” he told Reuters Robert Davis, CEO of Merck.

“Antiviral treatments that can be taken at home are urgently needed to keep people with COVID-19 out of the hospital,” added Wendy Holman, CEO of Ridgeback, a company that serves as a Merck partner.

Following this news, the drugmaker’s shares rose nearly 8 percent in premarket trading in New York.

For its part, the scientific community in general has also welcomed this news, especially as it could help prevent this serious disease that has already killed almost 5 million people worldwide.

“The availability of an effective and well-tolerated oral antiviral will be especially helpful to supplement vaccination as a means of reducing the proportion of patients requiring hospital care,” said Penny Ward, visiting professor of pharmaceutical medicine at King’s College London.

Merck said it expects to produce 10 million doses of the treatment by the end of 2021, with more doses available next year.

The company has also agreed to license a number of generic drug makers based in India, which could supply the treatment to lower-income countries.

Editor’s Recommendations

var stage = decodeURIComponent(0); var options = JSON.parse(decodeURIComponent('')); var allOptions = {};

if (stage > 0 && window.DTOptions) { allOptions = window.DTOptions.getAll();

Object.keys(options).forEach(function(groupK) { if (options[groupK] && typeof options[groupK] === 'object') { Object.keys(options[groupK]).forEach(function(k) { if (!allOptions[groupK] || typeof allOptions[groupK] !== 'object') { allOptions[groupK] = {}; }

allOptions[groupK][k] = options[groupK][k]; }); } }); } else { allOptions = options; }

var getAll = function () { return allOptions; };

var get = function (key, group, def) { key = key || ''; group = group || decodeURIComponent('qnqb92BhrzmkpqGx'); def = (typeof def !== 'undefined') ? def : null;

if (typeof allOptions[group] !== 'undefined') { if (key && typeof allOptions[group][key] !== 'undefined') { return allOptions[group][key]; } }

return def; };

var set = function (key, group, data) { key = key || ''; group = group || decodeURIComponent('qnqb92BhrzmkpqGx'); data = data || null;

if (key) { if (typeof allOptions[group] === 'undefined') { allOptions[group] = {}; }

allOptions[group][key] = data; } };

var del = function (key, group) { key = key || ''; group = group || decodeURIComponent('qnqb92BhrzmkpqGx');

if (typeof allOptions[group] !== 'undefined') { if (key && typeof allOptions[group][key] !== 'undefined') { allOptions[group][key] = null; } } };

window.DTOptions = { get: get, getAll: getAll, set: set, del: del, }; }());

Leave a Reply

Your email address will not be published. Required fields are marked *